This is the authors' abstract. We don't add key points for this paper.
OBJECTIVE: To assess BNT162b2 XBB.1.5-adapted COVID-19 vaccine uptake and effectiveness in children aged 5-17 years against emergency department (ED) encounters, urgent care (UC) visits, and hospital admissions. STUDY DESIGN: We conducted a retrospective cohort study using HealthVerity claims tokenized to California and Louisiana state vaccine registries. Children were followed using a time-varying exposure definition, with vaccinated time ≥14 days after vaccination, from September 25, 2023 through March 31, 2024. Incidence and incidence rates were calculated for vaccinated and unvaccinated time. Time-dependent Cox models were used to estimate adjusted hazard ratios, with percent vaccine effectiveness calculated as (1 - hazard ratio)∗100. RESULTS: Of 2 449 261 children aged 5-17 years who met inclusion criteria, 34 389 (1.4%) received an XBB.1.5-adapted BNT162b2 vaccine. Vaccination uptake was higher in California than Louisiana and increased with age. Half (51.2%) of children who received the XBB.1.5-adapted vaccine had received a 2022-2023 season BA.4/5 bivalent COVID-19 vaccine. In contrast, the majority (66.0%) of XBB.1.5 unvaccinated children had not received any prior COVID-19 vaccine. For all measured outcomes, the XBB vaccinated children had significantly lower incidence rates compared with those who did not receive any XBB vaccine. There were no COVID-19 associated hospitalizations in the vaccinated group. Adjusted vaccine effectiveness among children aged 5-17 years was 63% (95% CI: 39%-77%) against COVID-19-associated ED/UC encounters with similar results stratified by age and among varying outcomes. CONCLUSION: BNT162b2 XBB.1.5-adapted formulations provided significant protection in children aged 5-17 years against COVID-19 associated hospitalization and ED or UC visits. CLINICAL TRIAL REGISTRATION: NCT06199934 (https://clinicaltrials.gov/study/NCT06199934).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Andersen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: